Panel Discussion: Beyond PSMA – How Do We Realistically Identify New Targets to Take on with Radioligand Therapy

Time: 2:30 pm
day: Day Two


  • The success of Lutathera has re-demonstrated the value of RLT and provided another the proof of concept for this drug modality
  • It is essential for the industry to maintain this momentum and look to the future and find the next generation of targets so that we can properly assess their potential value
  • This session therefore covers how researchers are breaking new ground and taking risks on untested targets and indications; as well as picking apart the targets that big pharma has previously taken on with other therapeutics and yielded little success